EMEA-001348-PIP01-12-M01 - paediatric investigation plan

Cangrelor (tetrasodium)

Key facts

• Active Substance:
  Cangrelor (tetrasodium)
• Therapeutic area:
  Cardiovascular diseases
• Decision number:
  P/0203/2014
• PIP number:
  EMEA-001348-PIP01-12-M01
• Pharmaceutical form(s):
  Powder for concentrate for solution for infusion
• Condition(s) / indication(s):
  Prevention of non-site-specific embolism and thrombosis
• Route(s) of administration:
  Intravenous use
• Contact for public enquiries:

  The Medicines Company UK Ltd

  United Kingdom; Tel. [phone]; Fax [phone]; E-mail: [e-mail]

• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  08/08/2014

Decision

P/0203/2014: EMA decision of 8 August 2014 on the acceptance of a modification of an agreed paediatric investigation plan for cangrelor (tetrasodium), (EMEA-001348-PIP01-12-M01)

AdoptedReference Number: EMA/391891/2014